Wegovy maker Novo Nordisk down 4%, heads for worst day considering the fact that Oct

Wegovy maker Novo Nordisk down 4%, heads for worst day considering the fact that Oct


Novo Nordisk beats expectations but fails to impress some traders with new guidance

Shares of Danish pharmaceutical giant Novo Nordisk slid 4% on Friday, extending a 2.7% decline on Thursday as analysts pored about the facts of the firm’s first-quarter final results and monitored a opportunity rival body weight reduction procedure.

It puts the stock on observe for its sharpest everyday drop considering the fact that Oct 2023, in accordance to LSEG info.

The company claimed that gross sales for its blockbuster injectable weight reduction procedure Wegovy, a lot more than doubled to 9.38 billion Danish kroner ($1.4 billion). Novo Nordisk, which also would make diabetes treatment method Ozempic, said the increase in sales experienced offset a slight reduction in costs.

Novo Nordisk expects price ranges to fall even more as new entrants enter the sector, CFO Karsten Knudsen claimed on a media get in touch with, including that the enterprise was not viewing much proof of Wegovy consumers moving to other rival treatments.

Analysts predicted even better weight loss drug income in the quarter, and some famous that Novo Nordisk’s 2024 outlook elevate for both of those gross sales advancement and operating earnings was due to just one-off accounting changes.

“Even though we continue on to see Novo as a large-moat organization, with powerful intangible property bordering its cardiometabolic enterprise, we consider higher weight problems drug need and a shortage of provide have driven share price ranges previously mentioned their intrinsic price,” Karen Andersen, strategist at Morningstar, mentioned in a Thursday observe.

The boom in need for excess weight decline solutions saw Novo Nordisk overtake French luxury team LVMH to turn into Europe’s most beneficial corporation previous 12 months. Shares obtained 49% in 2023 and are up 25% year to date.

Novo Nordisk showed 'extraordinary growth' but faces competitive weight loss market: Novasecta

Income numbers were “a small bit light, expectations got in advance of themselves … and you however have these supply challenges at Novo,” Jared Holz, health-treatment equity strategist at Mizuho, advised CNBC’s “Rapidly Revenue” on Thursday.

Analysts at Stifel trimmed their focus on rate on the stock to 950 kroner, down from 960 kroner on Friday.

Pounds decline drug makers ended up meanwhile broadly reduced following U.S. firm Amgen said it was “quite happy” with initial trial success for its injectable being overweight cure MariTide.

The potential maximize in competition is hanging in excess of each Novo Nordisk and U.S. juggernaut Eli Lilly, which also elevated its outlook this 7 days, as far more excess weight loss players arise to shake up what has mostly been a two-horse race.

The two firms are consequently looking into new prospective fat loss treatments to retain an edge.

“When we appear at the full place, Novo and Lilly are dominating because they were being presently excellent existing gamers in diabetes. This weight problems market place is very tangential, it really is extremely uncomplicated for them to pivot a incredibly related individual population to obesity,” Holz mentioned.

It may possibly be probable for more recent gamers like Amgen to get 5% to 10% market share above time, or for the totality of competition to acquire 10% of the industry, but the advance of Eli Lilly and Novo Nordisk is “going to make it definitely hard,” Holz extra.

Outlook for Novo Nordisk is pretty bright, says Yuri Khodjamirian



Source

Media trailblazer Tom Rogers changes ‘raging bull’ stance on Netflix, sees worrisome signs
World

Media trailblazer Tom Rogers changes ‘raging bull’ stance on Netflix, sees worrisome signs

Former NBC Cable President Tom Rogers is dialing back his bullishness on Netflix. The media trailblazer, who was a self-proclaimed “raging bull” on Netflix, told CNBC’s “Fast Money” this week he’s starting to worry — and listed competition with free content on YouTube as a headwind. “[Netflix] still [has] more hit shows than all the […]

Read More
I went to a Costco in Japan—the variety of foods was ‘incredible’: Here’s the stuff you don’t really see in the U.S. stores
World

I went to a Costco in Japan—the variety of foods was ‘incredible’: Here’s the stuff you don’t really see in the U.S. stores

As a Japanese nutritionist living in the U.S., I love shopping for traditional foods that I grew up eating, such as seaweed, beans, matcha, multigrain rice, and sweet potatoes. I sometimes go to Costco to buy those staples in bulk. But during a recent trip to Japan, I had the chance to shop at the […]

Read More
Harvard expert: This 30-second strategy can make you more influential in everyday conversations
World

Harvard expert: This 30-second strategy can make you more influential in everyday conversations

Rehearsing a big presentation or jotting down some notes before a one-on-one meeting with your boss is normal. You should use a similar, truncated practice before casual interactions, recommends conversation expert Alison Wood Brooks: Take 30 seconds before greeting the other person to think about topics to go over, questions you want to ask or […]

Read More